RU2328287C2 - Схема приема erbb2 противоопухолевых агентов - Google Patents

Схема приема erbb2 противоопухолевых агентов Download PDF

Info

Publication number
RU2328287C2
RU2328287C2 RU2006102125/14A RU2006102125A RU2328287C2 RU 2328287 C2 RU2328287 C2 RU 2328287C2 RU 2006102125/14 A RU2006102125/14 A RU 2006102125/14A RU 2006102125 A RU2006102125 A RU 2006102125A RU 2328287 C2 RU2328287 C2 RU 2328287C2
Authority
RU
Russia
Prior art keywords
inhibitor
erbb2
methyl
test compound
bid
Prior art date
Application number
RU2006102125/14A
Other languages
English (en)
Russian (ru)
Other versions
RU2006102125A (ru
Inventor
Самит Кумар БХАТТАЧАРИА (US)
Самит Кумар Бхаттачариа
Ричард Деймиан КОННЕЛЛ (US)
Ричард Деймиан КОННЕЛЛ
Джеймс Дейл МОЙЕР (US)
Джеймс Дейл МОЙЕР
Джитеш Пранлал ДЖАНИ (US)
Джитеш Пранлал ДЖАНИ
Деннис Алан НОЕ (US)
Деннис Алан НОЕ
Стефанус Иоганнес СТЕЙН (US)
Стефанус Иоганнес СТЕЙН
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of RU2006102125A publication Critical patent/RU2006102125A/ru
Application granted granted Critical
Publication of RU2328287C2 publication Critical patent/RU2328287C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2006102125/14A 2003-08-18 2004-08-06 Схема приема erbb2 противоопухолевых агентов RU2328287C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49591903P 2003-08-18 2003-08-18
US60/495,919 2003-08-18

Publications (2)

Publication Number Publication Date
RU2006102125A RU2006102125A (ru) 2007-09-27
RU2328287C2 true RU2328287C2 (ru) 2008-07-10

Family

ID=34193358

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006102125/14A RU2328287C2 (ru) 2003-08-18 2004-08-06 Схема приема erbb2 противоопухолевых агентов

Country Status (18)

Country Link
US (1) US20050119288A1 (enExample)
EP (1) EP1658080A1 (enExample)
JP (1) JP2007502807A (enExample)
KR (2) KR20060037447A (enExample)
CN (1) CN1838959A (enExample)
AR (1) AR045268A1 (enExample)
AU (1) AU2004264726A1 (enExample)
BR (1) BRPI0413745A (enExample)
CA (1) CA2536140A1 (enExample)
CO (1) CO5670356A2 (enExample)
IL (1) IL173127A0 (enExample)
MX (1) MXPA06001989A (enExample)
NO (1) NO20061252L (enExample)
RU (1) RU2328287C2 (enExample)
SG (1) SG135193A1 (enExample)
TW (1) TW200522966A (enExample)
WO (1) WO2005016347A1 (enExample)
ZA (1) ZA200600517B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US8505468B2 (en) * 2002-11-19 2013-08-13 Sharp Kabushiki Kaisha Substrate accommodating tray
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US8318752B2 (en) 2003-09-19 2012-11-27 Astrazeneca Ab 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoyl-methyl)piperidin-4-yl]oxy}quinazoline, its pharmaceutically acceptable salts, and pharmaceutical compositions comprising the same
NZ550796A (en) 2004-05-06 2010-07-30 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides
GB0427131D0 (en) * 2004-12-10 2005-01-12 Glaxosmithkline Biolog Sa Novel combination
JP2008542354A (ja) * 2005-06-03 2008-11-27 ファイザー・プロダクツ・インク 癌治療におけるｅｒｂＢ２阻害剤と他の治療薬の併用
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
US8945573B2 (en) 2005-09-08 2015-02-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Targeted identification of immunogenic peptides
AU2006315512B2 (en) * 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
KR101086967B1 (ko) 2005-11-15 2011-11-29 어레이 바이오파마 인크. 과다증식성 질환의 치료를 위한 ｅｒｂｂ 유형 ｉ 수용체티로신 키나제 억제제로서의 ｎ4-페닐-퀴나졸린-4-아민유도체 및 관련 화합물
EP2010911A4 (en) * 2006-03-31 2009-05-13 Massachusetts Inst Technology TREATMENT OF EGF RECEPTOR MUTANTS EXPRESSING TUMORS
EP2004165A2 (en) * 2006-04-05 2008-12-24 Novartis Pharma AG Synergistic combinations of anticancer agents for treating cancer
AU2007319825B2 (en) 2006-11-14 2014-01-23 Ariad Pharmaceuticals, Inc. Oral formulations
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
ES2583377T3 (es) 2007-06-08 2016-09-20 Genentech, Inc. Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
US8252805B2 (en) * 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
WO2010027848A2 (en) * 2008-08-26 2010-03-11 Teva Pharmaceutical Industries Ltd. Forms of lapatinib compounds and processes for the preparation thereof
NZ594665A (en) 2009-03-20 2013-08-30 Genentech Inc Bispecific anti-her antibodies
WO2013078440A2 (en) * 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
CN110564604B (zh) * 2014-01-31 2023-09-29 凸版印刷株式会社 液滴的形成方法、生物分子分析方法及生物分子分析试剂盒
CN108473538B (zh) * 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130780C1 (ru) * 1992-04-10 1999-05-27 Рисерч Дивелопмент Фаундейшн Композиция и способ обработки неопластической клетки
RU2174977C2 (ru) * 1995-03-30 2001-10-20 Пфайзер Инк. Производные 4-(замещенного фениламино)хиназолина или их фармацевтически приемлемые соли, способ ингибирования рецепторной тирозинкиназы и фармацевтическая композиция
RU2198879C2 (ru) * 1996-09-25 2003-02-20 Зенека Лимитед Производные хиназолина, способы их получения, содержащие их фармацевтические композиции, способ достижения антиангиогенного и/или эффекта снижения проницаемости кровеносных сосудов у теплокровного животного
WO2003050108A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02012870A (es) * 2000-06-22 2003-05-14 Pfizer Prod Inc Derivados biciclicos sustituidos para el tratamiento del crecimiento celular anormal.
WO2003049740A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Quinazoline derivatives for the treatment of abnormal cell growth
EP1567506A4 (en) * 2002-11-20 2007-06-20 Array Biopharma Inc CYANOGUANIDINES AND CYANOAMIDINES AS INHIBITORS OF ERBB2 AND EGFR
AU2003303045A1 (en) * 2002-12-18 2004-07-09 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2130780C1 (ru) * 1992-04-10 1999-05-27 Рисерч Дивелопмент Фаундейшн Композиция и способ обработки неопластической клетки
RU2174977C2 (ru) * 1995-03-30 2001-10-20 Пфайзер Инк. Производные 4-(замещенного фениламино)хиназолина или их фармацевтически приемлемые соли, способ ингибирования рецепторной тирозинкиназы и фармацевтическая композиция
RU2198879C2 (ru) * 1996-09-25 2003-02-20 Зенека Лимитед Производные хиназолина, способы их получения, содержащие их фармацевтические композиции, способ достижения антиангиогенного и/или эффекта снижения проницаемости кровеносных сосудов у теплокровного животного
WO2003050108A1 (en) * 2001-12-12 2003-06-19 Pfizer Products Inc. Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
весь документ, см. с.7, 8, 10. Беликов В.Г. Фармацевтическая химия т.1. - М.: Высшая школа, 1993, с.43-47. *
формула. *

Also Published As

Publication number Publication date
EP1658080A1 (en) 2006-05-24
WO2005016347A1 (en) 2005-02-24
KR20060037447A (ko) 2006-05-03
KR20080014144A (ko) 2008-02-13
NO20061252L (no) 2006-05-16
AR045268A1 (es) 2005-10-19
CN1838959A (zh) 2006-09-27
BRPI0413745A (pt) 2006-10-24
CA2536140A1 (en) 2005-02-24
AU2004264726A1 (en) 2005-02-24
TW200522966A (en) 2005-07-16
JP2007502807A (ja) 2007-02-15
SG135193A1 (en) 2007-09-28
IL173127A0 (en) 2006-06-11
MXPA06001989A (es) 2006-05-17
ZA200600517B (en) 2007-02-28
CO5670356A2 (es) 2006-08-31
US20050119288A1 (en) 2005-06-02
RU2006102125A (ru) 2007-09-27

Similar Documents

Publication Publication Date Title
RU2328287C2 (ru) Схема приема erbb2 противоопухолевых агентов
Zhao et al. The clinical development of MEK inhibitors
RU2492864C2 (ru) Способ лечения рака, несущего мутации egfr
US11096947B2 (en) Combination products with tyrosine kinase inhibitors and their use
KR102871791B1 (ko) 병용 요법
JP6479812B2 (ja) 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ
KR20160100975A (ko) 제약 조합물
PT2182948E (pt) Utilização de imidazoquinolinas para o tratamento de doenças dependentes do egfr ou doenças que adquiriram resistência a agentes que têm como alvo membros da família egfr
KR20120096869A (ko) 포스포이노시티드 ３-키나제 억제제 및 항당뇨병 화합물의 조합물
WO2016011956A1 (en) Combination therapy
CA3243158A1 (en) THERAPEUTICALLY EFFECTIVE COMBINATION OF AN FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
BR112021010702A2 (pt) Métodos para terapia de câncer
CN101222850A (zh) 治疗对药物有抗性的癌症的方法
CN112237579B (zh) 药物组合及其用途
US20190169134A1 (en) Novel class of quinolone heterocyclic aromatic molecules for cancer treatment
US10202357B2 (en) Class of quinolone heterocyclic aromatic molecules for cancer treatment
CN115721649A (zh) 抑制突变型egfr的化合物及其应用
TW202126305A (zh) 使用egfr及cdk4/6抑制劑之組合以治療egfr突變體相關癌症
MX2008000900A (es) Combinacion que comprende pirimidil-amino-benzamidas y un inhibidor de flt-3 para el tratamiento de enfermedades proliferativas.
WO2026064479A1 (en) Cdk2 inhibitor for the treatment of kras mutant cancer
EA048458B1 (ru) Способы комбинированной терапии
HK1091745A (en) Dosing schedule for erbb2 anticancer agents

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20090807